dihydroartemisinin-piperaquine is one of 116 small molecule programs targeting Malaria. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
79 competitors in Malaria
Daraprim
dihydroartemisinin-piperaquine
Rabies Vaccine
Krintafel
Artemether-Lumefantrine (AL)
Artesunate-Amodiaquine
R21/matrix-M
Pyramax
Biltricide
Stelara
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources